Cancer cases weigh down Abivax’s Phase 3 maintenance data in ulcerative colitis
Abivax has proclaimed that its maintenance trial in ulcerative colitis delivered “landmark” results, and the drug's safety profile has previously been one of its main potential selling points. But Wall Street was rattled by malignancy ...
June 2, 2026 06:58 AM EDT R&D Cancer cases weigh down Abivax’s Phase 3 maintenance data in ulcerative colitis Reynald Castaneda Deputy Editor Abivax has proclaimed that its maintenance trial in ulcerative colitis delivered “landmark” results, and the drug’s safety profile has previously been one of its main … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER
comments(0)
5-min edit window · permanent after that